An encapsulated yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plague

PLoS Neglected Tropical Diseases

Volumn 6, Issue 2, 2012, Pages

  Derbise, Anne ^a   Marín, Alba ^a   Ave, Patrick ^a   Blisnick, Thierry ^a   Huerre, Michel ^a,b   Carniel, Elisabeth ^a   Demeure, Christian E ^a  

^a INSTITUT PASTEUR   (France)

^b INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMATIN ASSEMBLY FACTOR 1; LIVE VACCINE; UNCLASSIFIED DRUG; VACCINE; YERSINIA PSEUDOTUBERCULOSIS VACCINE; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CAF1 PROTEIN, YERSINIA PESTIS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PLAGUE VACCINE; RECOMBINANT VACCINE; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL VIRULENCE; CELLULAR IMMUNITY; CHROMATIN ASSEMBLY FACTOR 1 GENE; FECES ANALYSIS; FEMALE; GENE; GENE DELETION; HUMORAL IMMUNITY; IMMUNOASSAY; MASS IMMUNIZATION; MOUSE; NONHUMAN; PEYER PATCH; PLAGUE; PNEUMONIC PLAGUE; SINGLE DRUG DOSE; SPLEEN; TISSUE INJURY; YERSINIA PSEUDOTUBERCULOSIS; ANIMAL; BACTERIAL MEMBRANE; BIOSYNTHESIS; BLOOD; DISEASE MODEL; GENETICS; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; PATHOGENICITY; SURVIVAL; TH1 CELL; TH17 CELL; YERSINIA PESTIS;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; BACTERIAL PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; GENE DELETION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; PLAGUE; PLAGUE VACCINE; SURVIVAL ANALYSIS; TH1 CELLS; TH17 CELLS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRULENCE FACTORS; YERSINIA PESTIS; YERSINIA PSEUDOTUBERCULOSIS;

EID: 84857846732     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001528     Document Type: Article

References (63)

1. WHO (2009) Human plague: review of regional morbidity and mortality, 2004-2009. Wkly Epidemiol Rec 85: 40-45.
2. Arbaji A, Kharabsheh S, Al-Azab S, Al-Kayed M, Amr ZS, et al. (2005) A 12-case outbreak of pharyngeal plague following the consumption of camel meat, in north-eastern Jordan. Ann Trop Med Parasitol 99: 789-793.
3. Bertherat E, Bekhoucha S, Chougrani S, Razik F, Duchemin JB, et al. (2007) Plague reappearance in Algeria after 50 years, 2003. Emerg Infect Dis 13: 1459-1462.
4. McClean KL, (1995) An outbreak of plague in northwestern province, Zambia. Clin Infect Dis 21: 650-652.
5. Ratsitorahina M, Chanteau S, Rahalison L, Ratsifasoamanana L, Boisier P, (2000) Epidemiological and diagnostic aspects of the outbreak of pneumonic plague in Madagascar. Lancet 355: 111-113.
6. Bertherat E, Lamine KM, Formenty P, Thuier P, Mondonge V, et al. (2005) Major pulmonary plague outbreak in a mining camp in the Democratic Republic of Congo: brutal awakening of an old scourge. Med Trop (Mars) 65: 511-514.
7. Galimand M, Guiyoule A, Gerbaud G, Rasoamanana B, Chanteau S, et al. (1997) Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Engl J Med 337: 677-680.
8. Welch TJ, Fricke WF, McDermott PF, White DG, Rosso ML, et al. (2007) Multiple antimicrobial resistance in plague: an emerging public health risk. PLoS One 2: e309.
9. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, et al. (2000) Plague as a biological weapon- Medical and public health management. J Am Med Assoc 283: 2281-2290.
10. Meyer KF, Hightower JA, McCrumb FR, (1974) Plague immunization. VI. Vaccination with the fraction I antigen of Yersinia pestis. J Infect Dis 129: S41-45.
11. Oyston PCF, Williamson ED, Leary SEC, Eley SM, Griffin KF, et al. (1995) Immunization with live recombinant Salmonella typhimurium aroA producing F1 antigen protects against plague. Infect Immun 63: 563-568.
12. Chiuchiolo MJ, Boyer JL, Krause A, Senina S, Hackett NR, et al. (2006) Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen. J Infect Dis 194: 1249-1257.
13. Osorio JE, Powell TD, Frank RS, Moss K, Haanes EJ, et al. (2003) Recombinant raccoon pox vaccine protects mice against lethal plague. Vaccine 21: 1232-1238.
14. Heath DG, Anderson GW, Mauro JM, Welkos SL, Andrews GP, et al. (1998) Protection Against Experimental Bubonic and Pneumonic Plague By a Recombinant Capsular F1-V Antigen Fusion Protein Vaccine. Vaccine 16: 1131-1137.
15. Une T, Brubaker RR, (1984) Roles of V antigen in promoting virulence and immunity in Yersiniae. J Immunol 133: 2226-2230.
16. Williamson ED, Eley SM, Griffin KF, Green M, Russell P, et al. (1995) A new improved sub-unit vaccine for plague: The basis of protection. FEMS Immunol Med Microbiol 12: 223-230.
17. Blisnick T, Ave P, Huerre M, Carniel E, Demeure CE, (2008) Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain. Infect Immun 76: 3808-3816.
18. Achtman M, Zurth K, Morelli C, Torrea G, Guiyoule A, et al. (1999) Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis. Proc Natl Acad Sci USA 96: 14043-14048.
19. Zhou DS, Han YP, Dai EH, Song YJ, Pei DC, et al. (2004) Defining the genome content of live plague vaccines by use of whole-genome DNA microarray. Vaccine 22: 3367-3374.
20. Chain PS, Carniel E, Larimer FW, Lamerdin J, Stoutland PO, et al. (2004) Insights into the evolution of Yersinia pestis through whole-genome comparison with Yersinia pseudotuberculosis. Proc Natl Acad Sci USA 101: 13826-13831.
21. Derbise A, Lesic B, Dacheux D, Ghigo JM, Carniel E, (2003) A rapid and simple method for inactivating chromosomal genes in Yersinia. FEMS Immunol Med Microbiol 38: 113-116.
22. Lane MC, Alteri CJ, Smith SN, Mobley HL, (2007) Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract. Proc Natl Acad Sci U S A 104: 16669-16674.
23. Galen JE, Nair J, Wang JY, Wasserman SS, Tanner MK, et al. (1999) Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA. Infect Immun 67: 6424-6433.
24. Burrows TW, Bacon GA, (1953) The basis of virulence in Pasteurella pestis: an antigen determining virulence. Brit J Exp Pathol 37: 481-493.
25. Chanteau S, Rahalison L, Ralafiarisoa L, Foulon J, Ratsitorahina M, et al. (2003) Development and testing of a rapid diagnostic test for bubonic and pneumonic plague. Lancet 361: 211-216.
26. Reed I, Muench H, (1938) A simple method for estimating fifty percent end points. Am J Hyg 27: 493-497.
27. Mishell B, Shiigi S, (1980) Selected Methods in Cellular Immunology San Francisco W.H. Freeman and Co pp. 23-24.
28. Carniel E, (1999) The Yersinia high-pathogenicity island. Int Microbiol 2: 161-167.
29. Lindler LE, Klempner MS, Straley SC, (1990) Yersinia pestis pH-6 Antigen- Genetic, Biochemical, and Virulence Characterization of a Protein Involved in the Pathogenesis of Bubonic Plague. Infect Immun 58: 2569-2577.
30. Holmstrom A, Rosqvist R, Wolfwatz H, Forsberg A, (1995) Virulence plasmid-encoded YopK is essential for Yersinia pseudotuberculosis to cause systemic infection in mice. Infect Immun 63: 2269-2276.
31. Khader SA, Gaffen SL, Kolls JK, (2009) Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol 2: 403-411.
32. Priebe GP, Walsh RL, Cederroth TA, Kamei A, Coutinho-Sledge YS, et al. (2008) IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. J Immunol 181: 4965-4975.
33. Ye P, Garvey PB, Zhang P, Nelson S, Bagby G, et al. (2001) Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol 25: 335-340.
34. Lin JS, Kummer LW, Szaba FM, Smiley ST, (2011) IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection. J Immunol 186: 1675-1684.
35. Chain P, Regala W, Marieiro L, Souza B, Elliott J, et al. (2002) Whole genome sequencing of Yersinia pseudotuberculosis: Examining pathogen evolution among the recently emerged Yersinia. Abstracts of the General Meeting of the American Society for Microbiology 102.
36. Girard G, (1963) L'immunité dans l'infection pesteuse. Acquisitions apportées par 30 années de travaux sur la souche de "Pasteurella pestis EV". Biol Méd 52: 631-731.
37. Montminy SW, Khan N, McGrath S, Walkowicz MJ, Sharp F, et al. (2006) Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat Immunol 7: 1066-1073.
38. Zauberman A, Tidhar A, Levy Y, Bar-Haim E, Halperin G, et al. (2009) Yersinia pestis endowed with increased cytotoxicity is avirulent in a bubonic plague model and induces rapid protection against pneumonic plague. PLoS One 4: e5938.
39. Baker EE, Sommer H, Foster LE, Meyer E, Meyer KF, (1952) Studies on immunization against plague. I. The isolation and characterization of the soluble antigen of Pasteurella pestis. J Immunol 68: 131-145.
40. Bubeck SS, Dube PH, (2007) Yersinia pestis CO92 delta yopH is a potent live, attenuated plague vaccine. Clin Vaccine Immunol 14: 1235-1238.
41. Flashner Y, Mamroud E, Tidhar A, Ber R, Aftalion M, et al. (2004) Generation of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates. Infect Immun 72: 908-915.
42. Yang XH, Hinnebusch BJ, Trunkle T, Bosio CM, Suo ZY, et al. (2007) Oral vaccination with Salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague. J Immunol 178: 1059-1067.
43. Chattopadhyay A, Park S, Delmas G, Suresh R, Senina S, et al. (2008) Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Vaccine 26: 6329-6337.
44. McIntyre S, Knight SD, J. FL, (2004) Structure, assembly and applications of the polymeric F1 antigen of Yersinia pestis. In: Carniel E, Hinnebusch BJ, editors. Yersinia, molecular and Cellular Biology Wymondham Horizon Press pp. 363-407.
45. Knight SD, (2007) Structure and assembly of Yersinia pestis F1 antigen. Genus Yersinia: from Genomics to Function 603: 74-87.
46. Cornelius CA, Quenee LE, Elli D, Ciletti NA, Schneewind O, (2009) Yersinia pestis IS1541 transposition provides for escape from plague immunity. Infect Immun 77: 1807-1816.
47. Weening EH, Cathelyn JS, Kaufman G, Lawrenz MB, Price P, et al. (2011) The dependence of the Yersinia pestis capsule on pathogenesis is influenced by the mouse background. Infect Immun 79: 644-652.
48. Smiley ST, (2008) Current challenges in the development of vaccines for pneumonic plague. Expert Rev Vaccines 7: 209-221.
49. Quenee LE, Cornelius CA, Ciletti NA, Elli D, Schneewind O, (2008) Yersinia pestis caf1 variants and the limits of plague vaccine protection. Infect Immun 76: 2025-2036.
50. Smiley ST, (2008) Immune defense against pneumonic plague. Immunol Rev 225: 256-271.
51. Nakajima R, Brubaker RR, (1993) Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. Infect Immun 61: 23-31.
52. Parent MA, Wilhelm LB, Kummer LW, Szaba FM, Mullarky IK, et al. (2006) Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection. Infect Immun 74: 3381-3386.
53. Lin Y, Slight SR, Khader SA, (2010) Th17 cytokines and vaccine-induced immunity. Semin Immunopathol 32: 79-90.
54. Christie AB, Chen TH, Elberg SS, (1980) Plague in camels and goats: their role in human epidemics. J Infect Dis 141: 724-726.
55. Anderson GW, Worsham PL, Bolt CR, Andrews GP, Welkos SL, et al. (1997) Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis. Am J Trop Med Hyg 56: 471-473.
56. Green M, Rogers D, Russell P, Stagg AJ, Bell DL, et al. (1999) The SCID/Beige mouse as a model to investigate protection against Yersinia pestis. FEMS Immunol Med Microbiol 23: 107-113.
57. Hill J, Copse C, Leary S, Stagg AJ, Williamson ED, et al. (2003) Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect Immun 71: 2234-2238.
58. Cerutti A, Chen K, Chorny A, (2010) Immunoglobulin Responses at the Mucosal Interfaces. Annu Rev Immunol 29: 273-293.
59. Parkhill J, Wren BW, Thomson NR, Titball RW, Holden MTG, et al. (2001) Genome sequence of Yersinia pestis, the causative agent of plague. Nature 413: 523-527.
60. Pouillot F, Derbise A, Kukkonen M, Foulon J, Korhonen TK, et al. (2005) Evaluation of O-antigen inactivation on Pla activity and virulence of Yersinia pseudotuberculosis harbouring the pPla plasmid. Microbiology 151: 3759-3768.
61. Derbise A, Chenal-Francisque V, Pouillot F, Fayolle C, Prevost MC, et al. (2007) A horizontally acquired filamentous phage contributes to the pathogenicity of the plague bacillus. Mol Microbiol 63: 1145-1157.
62. Lesic B, Carniel E, (2005) Horizontal transfer of the high-pathogenicity island of Yersinia pseudotuberculosis. J Bacteriol 187: 3352-3358.
63. Demarre G, Guerout AM, Matsumoto-Mashimo C, Rowe-Magnus DA, Marliere P, et al. (2005) A new family of mobilizable suicide plasmids based on broad host range R388 plasmid (IncW) and RP4 plasmid (IncPalpha) conjugative machineries and their cognate Escherichia coli host strains. Res Microbiol 156: 245-255.